Baseline serum albumin levels for predicting progression-free survival in patients with non-hodgkin lymphoma: A single-center prospective study in Syria

BACKGROUND AND AIMS: A low baseline serum albumin (SA) level is considered an adverse prognostic indicator of various solid tumors and hematological malignancies. However, studies evaluating the relationship between SA levels and survival in non-Hodgkin lymphoma (NHL) patients are limited in Syria....

Full description

Bibliographic Details
Main Authors: Mariam Deeb Younis, Remal Abdulaziz Asaad, Firas Hasan Hussein
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Series:Journal of Applied Hematology
Subjects:
Online Access:http://www.jahjournal.org/article.asp?issn=1658-5127;year=2023;volume=14;issue=4;spage=287;epage=294;aulast=Younis
_version_ 1797222434388049920
author Mariam Deeb Younis
Remal Abdulaziz Asaad
Firas Hasan Hussein
author_facet Mariam Deeb Younis
Remal Abdulaziz Asaad
Firas Hasan Hussein
author_sort Mariam Deeb Younis
collection DOAJ
description BACKGROUND AND AIMS: A low baseline serum albumin (SA) level is considered an adverse prognostic indicator of various solid tumors and hematological malignancies. However, studies evaluating the relationship between SA levels and survival in non-Hodgkin lymphoma (NHL) patients are limited in Syria. Thus, this is the first study to assess the impact of baseline SA as an independent prognostic factor on progression-free survival (PFS) over 18 months (1.5 years) in Syrian NHL patients. METHODS: We prospectively analyzed patients diagnosed with de novo NHL who met the inclusion criteria and were admitted to the Chemotherapy and Radiotherapy Center at Tishreen University Hospital (TUH) in Latakia, Syria, between January 2021 and December 2021. The baseline SA concentration was measured. The PFS rate was estimated using the Kaplan–Meier method. Univariate and multivariate Cox proportional hazard regression analyses were carried out. RESULTS: Sixty patients in total were included. SA's optimal cutoff value for survival analysis was 3.95 g/dL, according to the receiver operating characteristic (ROC) curve. Patients were categorized into two groups based on that value, 25 (41.7%) had low (≤3.95 g/dL) and 35 (58.3%) had high SA levels (>3.95 g/dL). The PFS rate for 18 months was 56.7%. Kaplan–Meier curves showed that patients with low SA had a significantly inferior PFS rate (28% vs. 77.1%, P < .001). The independent prognostic significance of SA was verified by multivariate analysis. CONCLUSION: Low baseline SA levels (≤3.95 g/dL) could be a simple and effective factor in predicting poor 18-month PFS in Syrian NHL patients. To verify our findings, more extensive research is advised.
first_indexed 2024-04-24T13:21:16Z
format Article
id doaj.art-3efe62c0e07f428ba545f48d18651c2f
institution Directory Open Access Journal
issn 1658-5127
language English
last_indexed 2024-04-24T13:21:16Z
publishDate 2023-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of Applied Hematology
spelling doaj.art-3efe62c0e07f428ba545f48d18651c2f2024-04-04T14:30:01ZengWolters Kluwer Medknow PublicationsJournal of Applied Hematology1658-51272023-01-0114428729410.4103/joah.joah_62_23Baseline serum albumin levels for predicting progression-free survival in patients with non-hodgkin lymphoma: A single-center prospective study in SyriaMariam Deeb YounisRemal Abdulaziz AsaadFiras Hasan HusseinBACKGROUND AND AIMS: A low baseline serum albumin (SA) level is considered an adverse prognostic indicator of various solid tumors and hematological malignancies. However, studies evaluating the relationship between SA levels and survival in non-Hodgkin lymphoma (NHL) patients are limited in Syria. Thus, this is the first study to assess the impact of baseline SA as an independent prognostic factor on progression-free survival (PFS) over 18 months (1.5 years) in Syrian NHL patients. METHODS: We prospectively analyzed patients diagnosed with de novo NHL who met the inclusion criteria and were admitted to the Chemotherapy and Radiotherapy Center at Tishreen University Hospital (TUH) in Latakia, Syria, between January 2021 and December 2021. The baseline SA concentration was measured. The PFS rate was estimated using the Kaplan–Meier method. Univariate and multivariate Cox proportional hazard regression analyses were carried out. RESULTS: Sixty patients in total were included. SA's optimal cutoff value for survival analysis was 3.95 g/dL, according to the receiver operating characteristic (ROC) curve. Patients were categorized into two groups based on that value, 25 (41.7%) had low (≤3.95 g/dL) and 35 (58.3%) had high SA levels (>3.95 g/dL). The PFS rate for 18 months was 56.7%. Kaplan–Meier curves showed that patients with low SA had a significantly inferior PFS rate (28% vs. 77.1%, P < .001). The independent prognostic significance of SA was verified by multivariate analysis. CONCLUSION: Low baseline SA levels (≤3.95 g/dL) could be a simple and effective factor in predicting poor 18-month PFS in Syrian NHL patients. To verify our findings, more extensive research is advised.http://www.jahjournal.org/article.asp?issn=1658-5127;year=2023;volume=14;issue=4;spage=287;epage=294;aulast=Younisnon-hodgkin lymphomaprognostic factorprogression-free survivalserum albumin
spellingShingle Mariam Deeb Younis
Remal Abdulaziz Asaad
Firas Hasan Hussein
Baseline serum albumin levels for predicting progression-free survival in patients with non-hodgkin lymphoma: A single-center prospective study in Syria
Journal of Applied Hematology
non-hodgkin lymphoma
prognostic factor
progression-free survival
serum albumin
title Baseline serum albumin levels for predicting progression-free survival in patients with non-hodgkin lymphoma: A single-center prospective study in Syria
title_full Baseline serum albumin levels for predicting progression-free survival in patients with non-hodgkin lymphoma: A single-center prospective study in Syria
title_fullStr Baseline serum albumin levels for predicting progression-free survival in patients with non-hodgkin lymphoma: A single-center prospective study in Syria
title_full_unstemmed Baseline serum albumin levels for predicting progression-free survival in patients with non-hodgkin lymphoma: A single-center prospective study in Syria
title_short Baseline serum albumin levels for predicting progression-free survival in patients with non-hodgkin lymphoma: A single-center prospective study in Syria
title_sort baseline serum albumin levels for predicting progression free survival in patients with non hodgkin lymphoma a single center prospective study in syria
topic non-hodgkin lymphoma
prognostic factor
progression-free survival
serum albumin
url http://www.jahjournal.org/article.asp?issn=1658-5127;year=2023;volume=14;issue=4;spage=287;epage=294;aulast=Younis
work_keys_str_mv AT mariamdeebyounis baselineserumalbuminlevelsforpredictingprogressionfreesurvivalinpatientswithnonhodgkinlymphomaasinglecenterprospectivestudyinsyria
AT remalabdulazizasaad baselineserumalbuminlevelsforpredictingprogressionfreesurvivalinpatientswithnonhodgkinlymphomaasinglecenterprospectivestudyinsyria
AT firashasanhussein baselineserumalbuminlevelsforpredictingprogressionfreesurvivalinpatientswithnonhodgkinlymphomaasinglecenterprospectivestudyinsyria